Teva
Teva 'disappointed' by Irish consultants' boycott of its pharmaceuticals, company tells 'Post'
Teva told the Post it remains committed to working constructively with healthcare professionals across Ireland and to supporting patients through the "consistent supply of high-quality medicines."
The curse of being Israel's most valuable company
Mega deal: Teva acquires Emalex for approximately $900 million
IATI CEOs Forum meets in Kiryat Gat to discuss multinational industry resilience
FDA approves Teva’s generic of Mylan’s EpiPen
"...Patients living with severe allergies should have a lower-cost option."
A tribute to companies whose products have become Israeli icons worldwide
ZIM CEO Eli Glickman pays homage to the CEOs of Teva Israel, Mehadrin, Keter Plastic, and other prominent Israeli companies
Media Comment: Media-assisted legal irresponsibility
We need remind ourselves that all instruments of power, governmental and non-governmental, are never totally free of weaknesses.
Warren Buffett wagers big on Teva, and on Israel
The purchase initially sent share prices soaring by 12 percent.
Beit Berl College to re-train former Teva workers as chemistry teachers
The Education Ministry will cover the cost of tuition loans that will convert into grants after two years of teaching in the field.
Outrage as Teva charges $18,275 for generic drug in US
B "Teva Pharmaceutical's new generic version of the drug Syprine… will cost 28 times what Syprine cost in 2010. We have a crisis in drug prices in this country," Senator Bernie Sanders said.
Embattled Teva fined NIS 75m. for bribing foreign officials
This comes as the company is laying off thousands of workers in an effort to balance its books
Teva delays 33% of Jerusalem layoffs until 2019
The company making its first gesture, albeit a small one, to the workers and the Histadrut.
This week in Jerusalem: Life after Teva
A proposal was made that there should be an incentive to other firms in Jerusalem to absorb as many dismissed Teva employees as possible.
Teva’s collapse – Israel’s biotech recovery
Over the past two years, Teva lost $57b. of value, leaving it with a remaining market value of $19b. It owes about $35b.